Bristol-Myers Squibb Company (NYSE:BMY) Bernstein 41st Annual Strategic Decisions Conference May 28, 2025 3:30 PM ET
Company Participants
Chris Boerner – Chief Executive Officer & Chairman
Conference Call Participants
Courtney Breen – Bernstein
Courtney Breen
Fantastic. Hi, everyone. It’s great to have you here for this fireside, the first of our pharmaceutical fireside during the SDC. My name is Courtney Breen. I am the U.S. biopharma analyst here at Bernstein.
And I am thrilled to have Chris Boerner here with me today from Bristol. I will hand over to him to give you a little bit of his background, but also share some opening remarks on what’s going on at Bristol and the industry, and then we’ll dive into a series of questions.
Just a reminder, you’ll see some QR codes around, there are the ability to ask questions through the Pigeonhole. So please put those in there, so we can integrate them through the conversation today.
So, I’ll hand over to you, Chris.
Chris Boerner
Thanks, Courtney. It’s great to be here with everyone. I guess, the timing of this couldn’t be better. There’s obviously a lot going on in and around the industry, and I’m sure we’ll have a chance to dive into some of that.
But a little bit of background on where we are at Bristol. So, I’ve been in the role as CEO now since the end of 2023, November of ’23. And I think since then, we’ve been pretty consistently executing against a clear focus that we have, which is recognizing we’ve got a number of LOEs that are hitting the Company over a relatively short period of time. We set a very clear direction in November of ’23, which was that we were going to focus on emerging from this decade as one of the fastest-growing companies in the sector. And that’s the North
Credit: Source link
